Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Therapy | 18 | 2024 | 733 | 4.250 |
Why?
|
| Dependovirus | 15 | 2024 | 652 | 4.130 |
Why?
|
| Genetic Vectors | 17 | 2024 | 808 | 3.520 |
Why?
|
| Glycogen Storage Disease Type II | 2 | 2018 | 6 | 1.170 |
Why?
|
| alpha-Glucosidases | 2 | 2018 | 7 | 1.160 |
Why?
|
| Gene Editing | 3 | 2021 | 299 | 1.090 |
Why?
|
| Gene Transfer Techniques | 5 | 2024 | 303 | 0.970 |
Why?
|
| CRISPR-Cas Systems | 3 | 2021 | 333 | 0.800 |
Why?
|
| Immune System Diseases | 1 | 2022 | 17 | 0.760 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 105 | 0.710 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 91 | 0.700 |
Why?
|
| Muscle, Skeletal | 4 | 2024 | 674 | 0.600 |
Why?
|
| Lipid Metabolism, Inborn Errors | 2 | 2019 | 14 | 0.550 |
Why?
|
| Mitochondrial Diseases | 2 | 2019 | 20 | 0.540 |
Why?
|
| Muscular Diseases | 2 | 2019 | 46 | 0.540 |
Why?
|
| Transduction, Genetic | 5 | 2021 | 228 | 0.510 |
Why?
|
| Corpus Striatum | 1 | 2016 | 93 | 0.510 |
Why?
|
| Lung Diseases | 2 | 2017 | 170 | 0.470 |
Why?
|
| Huntington Disease | 1 | 2016 | 146 | 0.470 |
Why?
|
| MicroRNAs | 2 | 2021 | 616 | 0.460 |
Why?
|
| Central Nervous System | 4 | 2024 | 193 | 0.460 |
Why?
|
| RNA Interference | 1 | 2017 | 590 | 0.440 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 38 | 0.420 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2023 | 39 | 0.410 |
Why?
|
| Neurons | 2 | 2023 | 863 | 0.390 |
Why?
|
| Sudden Infant Death | 1 | 2012 | 22 | 0.390 |
Why?
|
| Lung | 1 | 2017 | 919 | 0.380 |
Why?
|
| Animals | 15 | 2024 | 19651 | 0.360 |
Why?
|
| Mice | 12 | 2023 | 10292 | 0.310 |
Why?
|
| Transgenes | 3 | 2023 | 177 | 0.290 |
Why?
|
| Humans | 17 | 2024 | 59360 | 0.290 |
Why?
|
| Glycogen | 2 | 2018 | 38 | 0.290 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 2 | 2019 | 9 | 0.260 |
Why?
|
| Liver | 3 | 2022 | 797 | 0.240 |
Why?
|
| Gene Expression | 3 | 2019 | 809 | 0.230 |
Why?
|
| Central Nervous System Diseases | 1 | 2024 | 56 | 0.220 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2024 | 87 | 0.220 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2024 | 62 | 0.210 |
Why?
|
| Dystrophin | 1 | 2023 | 31 | 0.210 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2023 | 84 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 2050 | 0.190 |
Why?
|
| Tay-Sachs Disease | 1 | 2022 | 34 | 0.190 |
Why?
|
| Immune Tolerance | 1 | 2022 | 172 | 0.180 |
Why?
|
| Immunity | 1 | 2021 | 101 | 0.180 |
Why?
|
| Gene Targeting | 1 | 2021 | 78 | 0.180 |
Why?
|
| Endonucleases | 1 | 2021 | 80 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 169 | 0.170 |
Why?
|
| Immunity, Innate | 2 | 2023 | 774 | 0.170 |
Why?
|
| Lentivirus | 2 | 2017 | 63 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 207 | 0.160 |
Why?
|
| Antigen Presentation | 1 | 2021 | 225 | 0.160 |
Why?
|
| Huntingtin Protein | 2 | 2016 | 138 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2019 | 162 | 0.150 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 1206 | 0.150 |
Why?
|
| Mice, Knockout | 4 | 2023 | 1994 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2019 | 223 | 0.150 |
Why?
|
| Enzyme Activation | 1 | 2018 | 359 | 0.140 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 7 | 0.140 |
Why?
|
| Gammaretrovirus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Potassium Chloride | 1 | 2017 | 14 | 0.140 |
Why?
|
| Methacholine Chloride | 1 | 2017 | 26 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 2017 | 19 | 0.140 |
Why?
|
| Extracellular Space | 1 | 2017 | 29 | 0.140 |
Why?
|
| Albuterol | 1 | 2017 | 24 | 0.140 |
Why?
|
| Drug Approval | 1 | 2017 | 25 | 0.140 |
Why?
|
| Carnitine | 2 | 2019 | 18 | 0.140 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 148 | 0.140 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Adenoviridae | 1 | 2017 | 117 | 0.130 |
Why?
|
| Bronchi | 1 | 2017 | 82 | 0.130 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 17 | 0.130 |
Why?
|
| Trachea | 1 | 2017 | 91 | 0.130 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 147 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 847 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 87 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 441 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 108 | 0.130 |
Why?
|
| Muscle Contraction | 1 | 2017 | 197 | 0.130 |
Why?
|
| Animals, Genetically Modified | 1 | 2016 | 280 | 0.130 |
Why?
|
| Calcium Signaling | 1 | 2017 | 153 | 0.120 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 213 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 281 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 203 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 3231 | 0.120 |
Why?
|
| Gangliosidosis, GM1 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Capsid Proteins | 1 | 2015 | 92 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 1 | 2016 | 354 | 0.120 |
Why?
|
| beta-Galactosidase | 1 | 2015 | 77 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2017 | 230 | 0.120 |
Why?
|
| Prognosis | 1 | 2018 | 1600 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2021 | 3067 | 0.110 |
Why?
|
| Immunoglobulin E | 2 | 2010 | 86 | 0.100 |
Why?
|
| Hypersensitivity | 2 | 2010 | 63 | 0.100 |
Why?
|
| Peptides | 1 | 2015 | 549 | 0.100 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2017 | 480 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2012 | 287 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1465 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 857 | 0.090 |
Why?
|
| CD3 Complex | 1 | 2010 | 63 | 0.090 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 74 | 0.080 |
Why?
|
| Interleukin-13 | 1 | 2009 | 37 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2010 | 190 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2009 | 88 | 0.080 |
Why?
|
| Phenotype | 1 | 2012 | 1137 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2018 | 5284 | 0.070 |
Why?
|
| Infant | 1 | 2012 | 1486 | 0.070 |
Why?
|
| Cytokines | 1 | 2010 | 912 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2023 | 116 | 0.050 |
Why?
|
| Axons | 1 | 2023 | 118 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 179 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 103 | 0.050 |
Why?
|
| Mutation | 1 | 2010 | 2456 | 0.050 |
Why?
|
| Male | 4 | 2024 | 27739 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2022 | 88 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2021 | 177 | 0.040 |
Why?
|
| Immune System | 2 | 2010 | 129 | 0.040 |
Why?
|
| Binding Sites | 1 | 2021 | 881 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 1151 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 297 | 0.030 |
Why?
|
| Cats | 1 | 2015 | 81 | 0.030 |
Why?
|
| Cricetulus | 1 | 2015 | 99 | 0.030 |
Why?
|
| CHO Cells | 1 | 2015 | 189 | 0.030 |
Why?
|
| Gangliosides | 1 | 2015 | 18 | 0.030 |
Why?
|
| Brain Stem | 1 | 2015 | 28 | 0.030 |
Why?
|
| Astrocytes | 1 | 2015 | 116 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 743 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 490 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2015 | 195 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 986 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 1984 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 20 | 0.020 |
Why?
|
| Aspergillus | 1 | 2010 | 11 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2009 | 19 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 99 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2009 | 148 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 480 | 0.020 |
Why?
|
| Female | 2 | 2021 | 30705 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 446 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 644 | 0.020 |
Why?
|
| Calcium | 1 | 2010 | 555 | 0.020 |
Why?
|
| Adult | 1 | 2023 | 15669 | 0.020 |
Why?
|